Retour

GENFIT (EPA:GNFT) GENFIT Announces Pivotal Publication of NIS4™ Technology to Identify Patients with At-Risk NASH in The Lancet Gastroenterology & Hepatology

Directive transparence : information réglementée

05/08/2020 08:30

22/02/2021 22:10

GENFIT: new market research data highlight potential of elafibranor in PBC

10/02/2021 22:10

GENFIT: 2021 Financial Calendar

09/02/2021 22:10

GENFIT Announces Publication of Positive Results from the Phase 2 Clinical...

28/01/2021 22:10

GENFIT Announces Two Key Appointments to the Executive Committee

27/01/2021 21:30

GENFIT: Technical Corrections to the Results of the January 25, 2021...

25/01/2021 19:30

GENFIT: Sweeping approval of OCEANEs buyback and amendments of terms

13/01/2021 22:10

GENFIT announces that its Extraordinary General Meeting on second notice...

12/01/2021 20:15

January 13, 2021 Extraordinary Shareholders Meeting: Wide support for the...

11/01/2021 22:10

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et...

06/01/2021 22:10

GENFIT to Present at Upcoming Investor Conferences and Host a PBC KOL Event

Voir tous les communiqués de GENFIT